Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Lurasidone

Plain-language summaryIntrigue 67 / 100

Lurasidone (Latuda) is a Japanese atypical antipsychotic from Sumitomo Dainippon, approved by the FDA in 2010. It blocks dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors in roughly balanced fashion, with very little activity at histamine or muscarinic receptors. That receptor profile gives it the lowest metabolic burden of the atypical antipsychotic class: minimal weight gain, minimal lipid or glucose disturbance, and minimal sedation. The 5-HT7 antagonism appears to contribute distinct procognitive and antidepressant effects, which is why it is approved for both schizophrenia and bipolar depression. The catch is that absorption is highly food-dependent: it must be taken with at least 350 calories or it does not work properly. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

59/100

Reference 5-HT7 antagonist among approved antipsychotics with a clean metabolic and sedation profile

Look, lurasidone doesn’t show up in our library because it needs introduction. It’s Latuda. It’s been an approved atypical antipsychotic since 2010, used by millions of patients, and the core D2/5-HT2A story is as well-understood as anything in that class gets. The reason it earns a place here isn’t the receptor profile everyone already knows — it’s the 5-HT7 component, and specifically what that means for investigators trying to do clean receptor-level work in bipolar depression or cognitive-outcome models.

The 5-HT7 receptor is underappreciated. It’s a Gs-coupled receptor widely expressed in the SCN, thalamus, and limbic circuitry, implicated in circadian entrainment, mood regulation, and cognitive processing in ways the traditional D2 and 5-HT2A blockade story doesn’t fully explain. Lurasidone’s Ki at 5-HT7 sits around 0.5 nM — making it the most potent 5-HT7 antagonist among all approved antipsychotics in clinical use. That’s not a small thing. When you want to study 5-HT7 contribution to antidepressant effect in a system that also needs regulatory-grade pharmacokinetics and an established safety profile, lurasidone is the reference tool.

What we like is the selectivity shape. Minimal H1 activity means the sedation confound that wrecks olanzapine and quetiapine in any cognition paradigm is largely absent. Minimal muscarinic means no acetylcholine bleed-through in cholinergic-adjacent readouts. The 5-HT1A partial agonism adds complexity but also mirrors the profile of vilazodone, making cross-comparison useful in bipolar depression studies. The food-dependent absorption (roughly 350 kcal required) is an annoyance worth noting in preclinical translational design, and akathisia is the dose-limiting signal in clinical contexts.

Where it loses ground is novelty and bench ceiling. The compound is fifteen years old. The clinical literature for schizophrenia and bipolar I depression is well-replicated — multiple phase 3 trials, FDA approval, substantial real-world data — but that evidence base answers clinical questions, not mechanistic ones. If you want a clean 5-HT7 probe with no D2 confound, SB-269970 or SB-656104 are more selective research tools. Lurasidone’s value is translational: it’s what you reach for when you want to connect receptor-level findings back to a clinically-validated pharmacological context.

Thats the honest case for it. Not a frontier compound, not a workhorse for basic receptor characterization, but a well-validated clinical reference tool with the most potent 5-HT7 profile of anything approved. For investigators running bipolar depression models, circadian disruption paradigms, or cognitive-outcome studies where 5-HT7 contribution is the specific variable, it’s genuinely useful and not easily replaced by something better positioned.

Novelty

33

Mechanism promise

60

In-category differentiation

63

Evidence quality

78

Translational signal

72

Research bench value

52

Rationale Lurasidone holds its place as the most potent 5-HT7 antagonist in clinical use, with a selective receptor shape that limits sedation and metabolic confounds useful for cognition and mood paradigms; its 2010 approval and fully characterized mechanism keep novelty and differentiation modest, and the overall score reflects real but bounded bench utility as a translational tool rather than a frontier research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic with 5-HT7 antagonism

A benzisothiazole atypical antipsychotic with prominent 5-HT7 receptor antagonism contributing to procognitive and antidepressant effects.

Abstract

Lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]-cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione; CAS 367514-87-2; molecular formula C28H36N4O2S; molecular weight 492.68) is a benzisothiazole atypical antipsychotic developed at Sumitomo Dainippon and approved by the FDA in 2010 under the trade name Latuda. The receptor profile features full D2 antagonism (Ki approximately 1 nM), potent 5-HT2A antagonism (Ki approximately 0.5 nM), 5-HT1A partial agonism (Ki approximately 6.4 nM), and prominent 5-HT7 antagonism (Ki approximately 0.5 nM, the most potent in clinical use). The 5-HT7 antagonism is associated with procognitive effects and improvement in bipolar depression. H1 and muscarinic activity is minimal, producing low sedation and metabolic burden compared to olanzapine and quetiapine; the principal limitation is dose-related akathisia. Plasma half-life is 18 hours; absorption requires food (approximately 350 kcal). Metabolism is via CYP3A4. Approved for schizophrenia (acute and maintenance), bipolar I depression (monotherapy or with lithium/valproate). Used as the reference 5-HT7-prominent antipsychotic.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-238Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Gaboxadol (THIP)

Our opinion on this compoundNiche research probe

61/100

The canonical extrasynaptic delta-GABA-A probe; therapeutically abandoned but mechanistically irreplaceable for tonic inhibition research

Look, gaboxadol is a weird one to rate because it exists in two completely separate stories simultaneously. The first story is a clinical failure: Lundbeck and Merck took it through Phase 3 in primary insomnia, watched patients experience disorientation and hallucinations, and pulled the plug in 2007. That story is over. The second story is the interesting one, and its the reason gaboxadol belongs in this library at all.

Here’s the thing about the mechanism. Most GABA pharmacology targets synaptic receptors, the alpha1/2/3-beta-gamma2 isoforms that benzodiazepines and z-drugs hit. Those receptors mediate phasic inhibition, fast transient signals. Gaboxadol does something different: it’s a superagonist at extrasynaptic GABA-A receptors bearing the delta subunit, primarily alpha4-beta3-delta and alpha6-beta3-delta, and those receptors mediate tonic inhibition, the continuous low-amplitude background current that sets the excitability baseline of a neuron. Thats a genuinely different biological variable, and most of the GABA pharmacology toolkit doesn’t let you isolate it cleanly.

We think the differentiation here is underappreciated. Muscimol hits both synaptic and extrasynaptic receptors indiscriminately. DS2, a delta-selective PAM, modulates the receptor but doesn’t agonize it directly. If you want to study what delta-subunit tonic GABA-A current actually does in a circuit, gaboxadol is effectively the only clean pharmacological lever. That’s a real niche, and it’s gotten more interesting since the brexanolone and zuranolone data validated the delta-subunit angle for neurosteroid-sensitive states. Labs working on PMDD biology, alcohol use disorder, stress-related changes in inhibitory tone, or sleep architecture at the subunit level are going to want this compound on the shelf.

The evidence picture is decent for a failed drug. Multiple Phase 3 trials ran to completion before the adverse event signal emerged. That means there’s actual human pharmacology data: real EEG effects, real sleep architecture changes, real CNS penetration confirmed by the adverse events themselves. Preclinical literature is solid and multi-lab. The translational signal is real but it points toward a wall therapeutically, which is why the score here isn’t higher overall.

Honestly, if you’re not working on GABA-A subunit biology specifically, this compound probably isn’t your priority. The clinical failure isn’t a reason to ignore it, but it does mean the research community actively using it is a specialist one. For those investigators, it’s close to indispensable. For everyone else, it’s a footnote in GABA pharmacology history with a genuinely interesting mechanism they probably won’t have occasion to use.

Novelty

48

Mechanism promise

68

In-category differentiation

72

Evidence quality

60

Translational signal

45

Research bench value

75

Rationale Gaboxadol failed Phase 3 as a hypnotic due to adverse psychiatric events, but the mechanism is intact and validated; it scores high on differentiation and bench value because no other compound selectively probes extrasynaptic delta-containing GABA-A receptors with the same precision, making it indispensable for labs working on tonic inhibition, neurosteroid sensitivity, or delta-subunit biology specifically.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective extrasynaptic GABA-A delta-subunit agonist

A 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol agonist selective for extrasynaptic GABA-A receptors containing the delta subunit; investigated as a hypnotic.

Abstract

Gaboxadol (THIP; 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; CAS 64603-91-4; molecular formula C6H8N2O2; molecular weight 140.14) is a selective extrasynaptic GABA-A receptor agonist developed at Lundbeck and Merck through the 1990s and 2000s. Distinct from benzodiazepines and barbiturates by selective binding to GABA-A receptor isoforms containing the delta subunit (alpha4-beta3-delta and alpha6-beta3-delta), which are predominantly extrasynaptic and mediate tonic (continuous, low-amplitude) inhibition rather than the phasic (high-amplitude, transient) inhibition mediated by synaptic alpha1/2/3-beta-gamma2 receptors. The compound is a superagonist at delta-containing receptors (efficacy greater than that of GABA itself). Phase 3 trials in primary insomnia (2007) were halted following adverse psychiatric events including disorientation and hallucinations; development was abandoned. The compound retains research utility as the canonical extrasynaptic delta-GABA-A agonist for academic GABA pharmacology and sleep architecture studies. Plasma half-life is approximately 1.5 to 2 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-255Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Liothyronine (T3)

Our opinion on this compoundEstablished workhorse

46/100

Canonical active thyroid hormone with strong clinical evidence but minimal research frontier value

Look, this is the canonical active thyroid hormone. Liothyronine has been around since before most researchers in this field were born, it binds TR-alpha and TR-beta with roughly 4x the affinity of T4, and the mechanism, genomic transcription of metabolic target genes through nuclear hormone receptor activation, was worked out thoroughly decades ago. That’s not a knock on the compound. It’s a knock on it as a research target in 2026.

What we like about T3 in the context of the library is that its pharmacokinetics make it a genuinely useful probe. The 2.5-day half-life versus T4’s 7-day half-life means you can actually titrate thyroid hormone state in a model organism or cell system with reasonable temporal precision. That has real bench utility for anyone studying metabolic gene regulation, cardiac hypertrophy models, or thyroid receptor biology. Its role as the reference standard for TR assays is legitimate and worth acknowledging.

Here’s the thing though: the interesting thyroid hormone pharmacology right now is happening at selective TR-beta agonists. Resmetirom just got FDA approval for MASH and that story, receptor-subtype selectivity to preserve metabolic benefit while shedding cardiac risk, is where the research conversation is. T3 hits both TR-alpha and TR-beta, which means it carries the full cardiac liability and doesn’t let you cleanly dissect receptor subtype contributions. As a research tool for that question, its nonselective profile is actually a limitation.

The STAR*D T3 augmentation data is real and worth knowing about. Adding T3 25 to 50 mcg to a partially-responding antidepressant did produce a 24.7% remission rate in the augmentation arm of that massive NCI-sponsored trial, which is a meaningful signal. But thats not new territory. The depression augmentation mechanism isn’t well-understood (thyroid hormone’s relationship to neurotransmitter sensitivity, particularly 5-HT1A and beta-adrenergic systems, remains speculative), and nobody is running novel T3 depression trials because the clinical question was largely answered.

We’d put T3 in the library as a reference compound and a functional tool for groups studying thyroid axis biology or receptor pharmacology. For someone building a metabolic research program or doing GH axis work where thyroid hormone status matters as a cofactor, having T3 on hand is just practical. But if you’re looking for something with genuine investigational upside in 2026, the TR-beta selective program is where you’d spend your reading time, not on T3 itself. The evidence is mature. The mechanism is settled. The frontier has moved on.

Novelty

18

Mechanism promise

28

In-category differentiation

38

Evidence quality

75

Translational signal

75

Research bench value

65

Rationale T3 scores well on evidence quality and translational signal as an approved drug with decades of clinical use and STAR*D-validated depression augmentation, but those strengths reflect maturity, not novelty; the compound’s low novelty, well-characterized nuclear receptor mechanism, and limited differentiation relative to emerging TR-beta selective agonists (resmetirom, MGL-3196) drag the overall to the mid-40s despite its reference-standard bench utility.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Active thyroid hormone (T3)

The active thyroid hormone triiodothyronine; faster-acting and more potent than levothyroxine, used in hypothyroidism, depression augmentation, and metabolic research.

Abstract

Liothyronine (3,3′,5-triiodo-L-thyronine, T3; CAS 6893-02-3; molecular formula C15H12I3NO4; molecular weight 650.97) is the active thyroid hormone, marketed as Cytomel for hypothyroidism. The compound binds thyroid hormone receptors (TR-alpha, TR-beta) with approximately 4-fold higher affinity than thyroxine (T4) and produces direct genomic effects on metabolic gene transcription without the conversion delay required for T4. Plasma half-life is 2.5 days, much shorter than T4’s 7-day half-life, producing more variable plasma levels but faster onset and offset. Approved for hypothyroidism (alternative or adjunct to levothyroxine), myxedema coma (intravenous), and as a thyroid suppression test. Off-label use in major depressive disorder augmentation (the STAR*D trial-supported strategy of T3 25 to 50 mcg added to a partially-responding antidepressant), fat loss, and bodybuilding cutting cycles. The cardiac risk is the principal limitation: T3 directly increases myocardial oxygen demand, producing tachycardia, atrial fibrillation, and angina at supratherapeutic doses. Used as the canonical T3 reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-288Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cannabidiol (CBD)

Our opinion on this compoundEstablished, active research

47/100

FDA-approved for refractory epilepsy but saturated mechanism space and near-zero novelty limit research priority

Look, CBD is one of those compounds where the public conversation has completely outrun the research conversation. It shows up in gummies, pet food, and sports recovery products, and that saturation is part of the problem for serious investigators. The compound itself isn’t boring exactly – the mechanism is genuinely multifactorial: CB2 partial agonism, TRPV1 agonism, GPR55 antagonism, 5-HT1A partial agonism, FAAH inhibition, and the reasonably interesting allosteric negative modulation at CB1. But most of these targets have been characterized for years, and the endocannabinoid literature is crowded enough that distinguishing signal from noise has become a real methodological problem in its own right.

The FDA approval story matters and deserves credit. Epidiolex’s regulatory acceptance for Dravet and Lennox-Gastaut was a genuine landmark, and the epilepsy RCT data holds up across multiple trials. That’s real translational signal in a pediatric population where the unmet need was severe. The problem is that for research purposes, the refractory epilepsy indication is mostly settled science. The interesting questions have moved into off-label territory – anxiety, neuroinflammation, sleep architecture, the interaction with the broader endocannabinoid system – and the evidence in those areas is genuinely messy. Product variability in commercial sources has contaminated a lot of published human work, and the clinical literature outside the approved indications is difficult to trust at face value.

What we think is worth attention here: CBD as a probe for endocannabinoid system biology. If your program needs clean CB1/CB2 dissociation, the negative allosteric modulation story is legitimately useful. The FAAH inhibition angle, and the resulting anandamide elevation, gives investigators a way to study tonic endocannabinoid signaling that you cant easily replicate with most other ligands. The CYP3A4 and CYP2D6 inhibition profile is also noteworthy – at research-relevant exposures CBD is a meaningful inhibitor of both, which makes it a confounder in combination studies and a useful tool for drug-drug interaction modeling.

What we don’t like: the novelty floor is basically zero at this point. If you’re looking for programs with discovery room, the phytocannabinoid space has been so aggressively mined commercially and academically that the ceiling is low. Minor cannabinoids like CBG and THCV carry more discovery potential right now. CBD earns its place as a reference standard and endocannabinoid probe, but honestly its hard to make the case that serious bench time should be allocated here in 2025 unless the program is specifically anchored in epilepsy mechanism work or endocannabinoid methodology. The score reflects a compound that is real, approved, and useful as a tool – not one that represents where the frontier is.

Novelty

22

Mechanism promise

42

In-category differentiation

48

Evidence quality

65

Translational signal

62

Research bench value

60

Rationale CBD scores reasonably on evidence and translational signal for the approved epilepsy indication but is heavily penalized by near-bottom novelty and a mechanism space that has been thoroughly mined for years; the compound retains genuine value as an endocannabinoid probe but is not where the research frontier is.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phytocannabinoid (non-intoxicating)

A non-psychotomimetic phytocannabinoid from Cannabis; FDA-approved for refractory pediatric epilepsy syndromes; widely used for anxiety, sleep, and inflammation.

Abstract

Cannabidiol (CBD; CAS 13956-29-1; molecular formula C21H30O2; molecular weight 314.46) is the principal non-intoxicating phytocannabinoid of Cannabis sativa, approved by the FDA in 2018 as Epidiolex for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex-associated seizures. Mechanism is multifactorial and incompletely characterized: minimal CB1 affinity (avoiding the THC-like psychoactivity), CB2 partial agonism, allosteric CB1 negative modulation (potentially attenuating THC effects), TRPV1 agonism, GPR55 antagonism, 5-HT1A partial agonism, and inhibition of fatty acid amide hydrolase (raising endogenous anandamide). Plasma half-life is 18 to 32 hours; metabolism is via CYP3A4 and CYP2C19, with CBD itself being a moderate inhibitor of CYP3A4 and CYP2D6 producing clinically relevant drug-drug interactions. Approved indications: refractory pediatric epilepsy. Off-label use is extensive (anxiety, sleep, pain, inflammation) with mixed clinical evidence and substantial product variability in the consumer market. Used as the canonical non-intoxicating phytocannabinoid in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-320Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Beta-Phenylethylamine (PEA)

Our opinion on this compoundNiche research probe

41/100

Endogenous TAAR1 reference compound with poor pharmacokinetics that limit utility beyond the trace amine niche

Look, PEA is genuinely interesting biology and a genuinely limited research tool, and that tension defines the score.

The TAAR1 story is real. Trace amine-associated receptor 1 is one of the more intellectually honest targets to emerge in monoamine pharmacology in the last two decades. It’s a GPCR that responds to endogenous trace amines and modulates dopaminergic and serotonergic neurotransmission without acting directly on those receptors. Thats a mechanistically clean and novel angle, and PEA is the canonical endogenous agonist with a Ki of roughly 700 nM at human TAAR1. The field has genuine traction: ulotaront (SEP-363856), a synthetic TAAR1 agonist developed by Sunovion, completed phase 2 trials in schizophrenia with signal that got people’s attention, and Roche’s RO5166017 has been a workhorse probe in preclinical TAAR1 circuit work. That context upgrades PEA from an old supplement to an endogenous reference compound for an active receptor target.

The problem is the pharmacokinetics, and it’s a serious one. Plasma half-life sits around five to ten minutes owing to rapid MAO-B-mediated degradation. Exogenous oral PEA is largely inactive as a result; meaningful tissue exposure requires MAO-B inhibition, and the selegiline combination used in preclinical trace amine work introduces confounders that make clean TAAR1-attribution difficult. When you compare PEA to synthetic TAAR1 probes with proper selectivity profiles and half-lives long enough to actually run behavioral assays, PEA becomes a baseline reference rather than a primary tool. It tells you where the endogenous system sits; it doesn’t let you interrogate TAAR1-dependent physiology without significant pharmacokinetic caveats layered on top.

The evidence base reflects that limitation honestly. There’s a meaningful multi-lab neurochemistry literature on PEA’s role in trace amine physiology, and some recurring correlational human data, specifically urinary PEA excretion correlations with depressive episodes that thread through the older psychiatric literature. Effect sizes are modest and the mechanistic link remains indirect. What there isn’t is a clean clinical program built around PEA itself, because the PK problem has always redirected pharmaceutical development toward more stable TAAR1 agonists rather than the endogenous parent compound.

We think the bench value here is real but narrow. If you’re running a TAAR1 biology program, you need PEA as your endogenous reference; it’s what every TAAR1 paper anchors comparisons against. That’s genuine utility and we credit it. But if you’re not specifically in the trace amine space, the compound adds little that a better-designed synthetic probe couldn’t do more cleanly. The supplement community has built a reputation around it that the pharmacological picture doesn’t support, and we score accordingly.

Novelty

28

Mechanism promise

60

In-category differentiation

38

Evidence quality

44

Translational signal

28

Research bench value

52

Rationale PEA scores on mechanism interest because TAAR1 is a genuinely active research target with real pharma investment, but its extremely short half-life and the availability of superior synthetic TAAR1 probes constrain bench value to the narrow endogenous-reference role; supplement-market hype inflates its reputation well past the pharmacological reality.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous trace amine / TAAR1 agonist

An endogenous trace amine; a TAAR1 agonist found at low concentrations in mammalian brain; structurally the parent of amphetamine.

Abstract

Beta-phenylethylamine (PEA; 2-phenylethylamine; CAS 64-04-0; molecular formula C8H11N; molecular weight 121.18) is an endogenous trace amine produced by decarboxylation of L-phenylalanine. The compound is found at low concentrations in mammalian brain (nM range) and in dietary sources including chocolate, cheese, and certain fermented foods. PEA is the prototype TAAR1 agonist (Ki approximately 700 nM at human TAAR1) with secondary effects on monoamine release and inhibition of MAO-B. Plasma half-life is extremely short (approximately 5 to 10 minutes) owing to rapid MAO-B-mediated degradation; exogenous oral PEA is therefore largely inactive without MAO-B inhibition (selegiline combination is used to extend duration). Behavioral and physiological effects parallel amphetamine but with shorter duration and lower potency. Used as the canonical endogenous TAAR1 agonist in trace amine research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-335Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Low-Dose Naltrexone (LDN)

Our opinion on this compoundNiche research probe

48/100

Genuinely interesting neuroimmune probe with patchy clinical evidence and an old backbone

Look, the compound itself is ancient. Naltrexone got FDA approval in 1984, and the low-dose angle dates to Bernard Bihari’s clinical observations in the late 1980s. So when we talk about LDN as a research target, we’re not talking about freshness. What we are talking about is a genuinely unusual pharmacological story that most people in the opioid receptor space still dont fully understand.

Here’s the thing that makes LDN interesting: the mechanism isn’t just “antagonize the mu receptor at low dose and call it a day.” The working model involves a brief 4-6 hour blockade that triggers compensatory receptor upregulation and increases in endogenous opioid synthesis — net effect is actually elevated opioid tone over baseline, the opposite of what you’d expect. Layer on top of that the TLR4 antagonism story, where naltrexone’s action on microglial Toll-like receptor 4 attenuates neuroinflammatory signaling through a completely separate pathway. That’s a two-pronged mechanism with real conceptual bite, and the neuroimmune piece is what drives most of the current bench interest.

The problem is the evidence base. We have clinical trials across fibromyalgia, multiple sclerosis, Crohn disease, Hashimoto thyroiditis, and CRPS — but almost all of them are small-N, single-center, and methodologically inconsistent. The Penn fibromyalgia work from Younger’s group is probably the most methodologically serious, and even that produced modest effect sizes. There’s no phase 2/3 replication that would let you say “this is settled.” The translational signal is real in the sense that human subjects clearly respond to something, but “why” remains incompletely characterized and the effect magnitude across populations is not compelling.

What we think is genuinely valuable here is the bench probe application: LDN is a useful tool if you’re studying microglial TLR4 signaling, paradoxical receptor pharmacology, or neuroimmune crosstalk. You can ask questions with it that you can’t ask as cleanly with other compounds in this space. The compounding availability is solid and the base compound’s pharmacokinetics are extremely well-characterized, which means experimental design is tractable. For investigators working at the neuroimmune interface, having LDN in the toolkit makes sense.

What we don’t like: the clinical literature is genuinely messy. Patient advocacy communities have generated most of the pressure to study LDN, which introduces selection bias and publication pressure that makes the human signal harder to parse. If you’re trying to build a rigorous case for any single indication, you’re working against decades of underpowered trials. Interesting compound, credible mechanism, limited evidence base. That combination lands it squarely in the useful-but-not-compelling range for most research programs outside of the neuroimmune niche it was built for.

Novelty

35

Mechanism promise

58

In-category differentiation

52

Evidence quality

42

Translational signal

47

Research bench value

58

Rationale LDN’s dual mechanism — paradoxical opioid tone upregulation plus TLR4/microglial antagonism — is more interesting than a plain receptor story, but naltrexone is a 1984 FDA approval and the LDN angle has been circulating since Bihari’s work; novelty is limited. Evidence across MS, fibromyalgia, and Crohn’s consists of small-N trials with mixed methodology, which floors both evidence quality and translational signal and keeps the overall in the high-40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Mu-opioid antagonist (low-dose immunomodulatory use)

A mu-opioid antagonist used at low doses (1.5 to 4.5 mg) for autoimmune and chronic pain conditions; mechanism via transient opioid blockade and TLR4 modulation.

Abstract

Naltrexone ((5alpha)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one; CAS 16590-41-3; molecular formula C20H23NO4; molecular weight 341.40) is a long-acting mu-opioid antagonist approved by the FDA in 1984 (ReVia, Vivitrol) for opioid and alcohol use disorders at standard doses (50 mg/day or 380 mg monthly depot). The low-dose application (LDN, 1.5 to 4.5 mg/day) was developed by Bernard Bihari in the 1980s and has been adopted in immunology and chronic pain communities. Mechanism is multifactorial and incompletely characterized: brief, transient mu-opioid antagonism (only 4 to 6 hours per dose) triggers compensatory upregulation of endogenous opioid synthesis and receptor expression, producing a paradoxical increase in opioid-mediated tone over baseline; secondary TLR4 antagonism on microglia attenuates neuroinflammation. Approved indications: opioid and alcohol use disorders (standard dose). Off-label LDN use in multiple sclerosis, Crohn disease, fibromyalgia, complex regional pain syndrome, and Hashimoto thyroiditis is supported by small clinical trials with mixed methodology. Plasma half-life is approximately 4 hours. Used as a research compound for paradoxical opioid pharmacology and neuroimmune modulation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-351Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
N-Acetylcysteine (NAC)

Our opinion on this compoundResearch workhorse

45/100

Canonical glutathione precursor and reliable bench probe, but novelty is low and the frontier research case is modest

Yeah, NAC is one of those compounds where the experienced bench scientist’s reaction is “of course we carry it” rather than “I want to study this.” FDA approved in 1963, the canonical acetaminophen antidote, and the reference glutathione precursor for oxidative stress work for decades. That pedigree is both its strength and the main reason it sits mid-table in this library.

The core mechanism is textbook at this point. NAC hydrolyzes to L-cysteine, replenishes intracellular GSH, and in the acetaminophen overdose context that pharmacology is about as well-validated as anything in clinical medicine. The direct mucolytic activity via disulfide bond reduction in mucus glycoproteins is the original Mucomyst story. What we find more interesting is the secondary angle: NAC’s role as substrate in the cystine-glutamate antiporter (system Xc-) pathway. Work from the Bridges lab at Medical University of South Carolina and others flagged this as the mechanistic driver behind effects in compulsive behaviors and addiction phenotypes. Thats a genuinely useful research frame. But its not new. The accumulation of system Xc- literature has been going on since roughly 2004-2008, and the novelty budget is largely spent.

Evidence quality is actually strong relative to where NAC sits on the novelty axis. The core FDA indications are essentially definitive. The psychiatric literature is more complicated but real. Deepmala et al. (2016) meta-analyzed NAC across psychiatric conditions and found modest but consistent signal for OCD and addictive behaviors. The Oliver group’s addiction work, plus multiple RCTs in gambling disorder and cannabis dependence, gives you a replication record that most compounds in this space cant touch. Effect sizes sit in the small-to-moderate range and some Cochrane-adjacent reviews are skeptical, but the translational signal is there and its not going away.

As a bench probe, NAC remains genuinely valuable. If you’re running glutathione depletion experiments, studying NAPQI hepatotoxicity mechanisms, probing system Xc- pharmacology in neuronal cultures, or need a reference standard for redox assays, NAC is the go-to. That utility is real and it raises the bench value score meaningfully relative to what the novelty picture alone would suggest. The differentiation picture is mixed: NAC basically owns the acetaminophen-antidote niche and is the canonical GSH precursor, but competitors like glycine-NAC co-administration (the Sekhar lab work) and liposomal GSH formulations are creating noise in the supplemental research space.

Honestly, the research calculus here is straightforward. NAC is answering questions that mostly got asked a long time ago. The differentiated angles, specifically system Xc- pharmacology and addiction phenotype studies, have enough residual signal to make it worth carrying in a serious library. But the mechanism isnt surprising anyone and the novelty needle is essentially flatlined. What we like: multi-indication evidence base, genuine probe value for GSH and redox biology, well-characterized sourcing. What we dont like: mechanism is mature, psychiatric effect sizes are modest, and there isnt a fresh angle that makes this a priority for anyone not already deep in glutamate or redox biology. Solid catalog compound, not a frontier target.

Novelty

20

Mechanism promise

28

In-category differentiation

45

Evidence quality

68

Translational signal

62

Research bench value

68

Rationale NAC scores well on evidence quality and bench utility as the reference glutathione precursor and FDA-approved standard of care, but its 1963 approval date and fully characterized core mechanism keep novelty and mechanism-promise scores low; the system Xc- angle for neuropsychiatric indications is real but has been accumulating in the literature since the mid-2000s and isnt moving fast enough to change the picture.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Glutathione precursor / mucolytic / antioxidant

N-acetyl-L-cysteine; a glutathione precursor used as a mucolytic, the antidote for acetaminophen overdose, and a candidate for neuropsychiatric and metabolic conditions.

Abstract

N-acetylcysteine (NAC; CAS 616-91-1; molecular formula C5H9NO3S; molecular weight 163.20) is the N-acetylated derivative of L-cysteine, approved by the FDA in 1963 as a mucolytic and acetaminophen overdose antidote. Mechanism: NAC is hydrolyzed to L-cysteine, the rate-limiting precursor for glutathione (GSH) biosynthesis; NAC administration rapidly replenishes intracellular GSH. The acetyl group also has direct mucolytic activity through disulfide bond reduction in mucus glycoproteins (the original FDA indication, Mucomyst). In acetaminophen overdose, replenished GSH conjugates the toxic NAPQI metabolite, preventing hepatocellular necrosis. Plasma half-life is approximately 6 hours. Off-label and research uses are extensive: OCD, trichotillomania, gambling disorder, addiction (cocaine, alcohol, cannabis), bipolar disorder, schizophrenia, and as a chemoprotective antioxidant. The clinical evidence is mixed; meta-analyses generally support modest effects in OCD and addictive behaviors. The compound is sold as both a prescription drug (oral, IV, inhaled) and as an OTC supplement. Used as the canonical glutathione precursor in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-369Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Hordenine

Plain-language summaryIntrigue 35 / 100

Hordenine (N,N-dimethyl-tyramine) is a phenethylamine alkaloid found in germinating barley and several cacti. It is a weak MAO-B inhibitor and a weak monoamine reuptake inhibitor, and the combination slows the breakdown of dopamine and short-lived trace amines like beta-phenylethylamine (PEA). The supplement use angle is to pair it with PEA, where the MAO-B inhibition extends PEA’s normally minutes-long duration into something noticeable. Plasma half-life is one to two hours. The actual pharmacological effects in humans at supplement doses are modest, and most enthusiasm comes from extrapolation rather than human trials. Botanical MAO-B reference compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

22/100

Weak botanical MAO-B inhibitor with a narrow PEA-extension niche and no compelling independent research case

Look, hordenine isn’t a bad compound. It’s just not an interesting one, and those are different problems. N,N-dimethyl-tyramine has been in the literature long enough that its pharmacological ceiling is well-understood, and that ceiling is low. Weak MAO-B inhibition, weak monoamine reuptake inhibition, plasma half-life around 1-2 hours. Nothing there surprises anyone who’s read the trace amine literature from the last two decades.

The mechanism isn’t without logic. MAO-B catabolizes beta-phenylethylamine aggressively, which is why PEA’s endogenous half-life is measured in minutes despite its potent monoaminergic effects. Hordenine slows that degradation, so stacking it with PEA extends PEA’s window of action. That’s the entire scientific case for hordenine as a research-relevant compound, and its essentially a delivery-extension story, not a primary mechanism story. We like that the trace amine/TAAR1 space has gotten serious attention in the last decade, but hordenine isnt the probe you reach for when you want to study it properly.

On differentiation, hordenine loses badly to actual pharmacological MAO-B inhibitors. Selegiline is selective, potent, and has a massive preclinical and clinical literature. Rasagiline similarly. Safinamide adds a sodium channel component that gives it real mechanistic depth. Hordenine against those tools is like using a butter knife for something that needs a scalpel. Its botanical origin is sometimes cited as a feature, and we suppose it is if you’re running naturalistic formulation studies, but that’s a thin reason to prioritize it on a serious bench program.

Evidence quality is limited. Theres reasonable in vitro and rodent preclinical data supporting the MAO-B inhibitory activity, but multi-lab replication is sparse and human-facing data at supplement-relevant doses is essentially observational and anecdotal. The pharmacodynamic effects in humans are described uniformly as modest, which is consistent with the weak binding affinities measured in vitro. No robust phase 1 or 2 clinical work anchors the human translation.

Honestly, the only scenario where hordenine earns a place in an active research program is if the program specifically needs a botanical source of mild MAO-B modulation, or if PEA pharmacokinetics are the direct object of study. Both are narrow. Outside those cases, its a mature, well-understood adjunct compound that doesn’t open new questions, doesnt offer unique probe value, and doesn’t differentiate from better tools. A serious investigator would deprioritize this in favor of almost anything else in the phenethylamine or trace amine space.

Novelty

22

Mechanism promise

22

In-category differentiation

18

Evidence quality

25

Translational signal

20

Research bench value

28

Rationale Hordenine scores low across every axis because it’s a decades-old, well-characterized botanical alkaloid whose pharmacology is unremarkable: weak MAO-B inhibition, weak monoamine reuptake inhibition, modest human effect size at supplement doses, and zero differentiation from superior pharmacological tools in its class. Its only credible research angle is as a botanical adjunct extending PEA’s short half-life, which is a narrow probe application rather than a standalone research program.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenethylamine MAO-B inhibitor / mild stimulant

N,N-dimethyl-tyramine; a phenethylamine alkaloid found in barley sprouts; a weak MAO-B inhibitor used as a stimulant adjunct.

Abstract

Hordenine (N,N-dimethyl-tyramine; CAS 539-15-1; molecular formula C10H15NO; molecular weight 165.23) is a phenethylamine alkaloid found in germinating barley (Hordeum vulgare) and several cacti. The compound is a weak monoamine oxidase B inhibitor and a weak monoamine reuptake inhibitor; the combined activity slows the degradation of dopamine and trace amines including beta-phenylethylamine (PEA), prolonging their action. Used as a supplement, particularly in combination with PEA where the MAO-B inhibition extends PEA’s normally minutes-long duration. Plasma half-life is approximately 1 to 2 hours. The pharmacological effects in humans at supplement doses are modest. Used as a botanical MAO-B inhibitor in research and in supplement formulations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-385Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Org-26576

Plain-language summaryIntrigue 40 / 100

Org-26576 is a sulfonamide AMPA potentiator developed at Organon. Phase 2 trials investigated it in major depressive disorder and ADHD. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

39/100

Discontinued Merck ampakine with modest Phase 2 signal and limited bench accessibility

AMPA receptor positive allosteric modulators have a genuinely compelling theoretical basis. By slowing channel deactivation and desensitization, they amplify glutamatergic throughput, drive BDNF expression, and modulate synaptic plasticity in ways that NMDA-targeted compounds simply can’t replicate. The mechanism is interesting, the rationale for depression and cognitive enhancement is plausible, and Org-26576 at least made it further through clinical development than most ampakines. Organon built the program, Schering-Plough inherited it, Merck finished it, and then walked away. That arc matters.

Here’s the thing about the AMPA PAM class: it has a long, frustrating history of preclinical promise colliding with clinical disappointment. CX516, CX717, farampator, LY404187 and a dozen others all generated real excitement in the late 1990s through mid-2000s, showed plausible Phase 1 tolerability, and then produced Phase 2 data described in almost identical language to whats in Org-26576’s dossier: modest cognitive endpoint improvements, no adverse signal. In pharmaceutical development that’s a polite way of saying the delta wasn’t there. When a well-resourced pharma group has already invested in full IND-enabling studies and a Phase 2 execution and still walks away, the independent research community is left with a thin published evidence base and whatever can be reconstructed from conference abstracts.

The sulfonamide scaffold is a genuine chemical differentiator. Org-26576 is not just a CX-class analog; the sulfone headgroup changes the binding geometry and potentially the kinetic profile of AMPA channel modulation in ways that aren’t fully worked out in the public literature. For a group specifically investigating structure-activity relationships across AMPA PAM chemotypes, or trying to understand whether kinetic selectivity differences between ampakine classes have functional consequences, this compound represents a well-defined clinical-stage data point. It cleared human safety. That’s real. It’s also about the extent of the positive case.

Sourcing is a serious obstacle. The compound is rarely available in research-chemical-grade markets, which means bench accessibility is low and reproducibility across labs is essentially hypothetical. Researchers who want an AMPA PAM probe with documented methodology would typically reach for farampator, which has more published protocol support, or look at the newer BNT-III class compounds generating current literature. We think the under-characterized sulfonamide angle is the only genuine hook here, and it’s a narrow one.

Honestly, this scores where it does because the class is mature, the clinical outcome was modest, the compound is hard to source, and the evidence base is largely gated behind Merck’s development files. Interesting chemistry in an underdelivering class isnt the same as a compelling research target.

Novelty

38

Mechanism promise

57

In-category differentiation

30

Evidence quality

40

Translational signal

35

Research bench value

28

Rationale Org-26576 earns modest scores across the board: the sulfonamide AMPA PAM scaffold has chemical interest but the class has a consistent history of clinical underdelivery, and Merck’s discontinuation leaves the evidence base thin and sourcing nearly nonexistent for independent labs. Mechanism score is the brightest spot; differentiation and bench value are both dragged down by limited availability and a crowded class where better-characterized probes already exist.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sulfonamide AMPA potentiator

An Organon/Merck ampakine that reached Phase 2 in major depressive disorder.

Abstract

Org-26576 is a sulfonamide-class AMPA receptor positive allosteric modulator developed by Organon (subsequently Schering-Plough, Merck) for cognitive enhancement in major depressive disorder and other indications. The compound advanced through Phase 2 trials with results consistent with the ampakine class profile (modest cognitive endpoint improvements, no adverse signal). The development program was discontinued under Merck. Pharmacokinetics: plasma half-life approximately 5 hours; oral bioavailability adequate. The compound is rarely available in research-chemical-grade markets.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-060Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
MK-677 (Ibutamoren)

Plain-language summaryIntrigue 72 / 100

MK-677 (Ibutamoren) is a small-molecule growth hormone releaser that mimics ghrelin. Unlike GHRPs, it is orally active because it is not a peptide. It produces sustained growth hormone elevation, increased appetite, and improved sleep, often used in research contexts as an oral GH releaser. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

48/100

Oral GH secretagogue that defines its niche but Phase 3 failure and 1990s vintage cap the ceiling

Look, MK-677 occupies a genuinely interesting position in the GH secretagogue class: it’s the compound that answered the question “can you get sustained GH elevation orally, once a day, without injections?” The answer is yes, and that answer still matters to investigators who want to study GH/IGF-1 biology in models that don’t require daily subcutaneous dosing. Merck’s program produced real clinical data: the Chapman et al. JCEM studies showed sustained IGF-1 elevation and lean body mass increases over 12 to 24 months in elderly subjects, which is a rare duration for a secretagogue trial and a genuinely useful data set.

The mechanism is well-defined: MK-677 is a high-affinity ghrelin receptor (GHS-R1a) agonist. It mimics ghrelin’s pulsatile GH secretagogue effect while bypassing the peptide limitations that make most GHRPs injection-dependent. The oral bioavailability is the real story here. Compared to ipamorelin or GHRP-6, which have essentially identical receptor pharmacology but require parenteral delivery, MK-677 lets you run longer-duration protocols without compliance issues. Thats a meaningful tool advantage that nothing else in the class currently matches.

What we don’t like: this is a 1990s Merck compound. The mechanism is single-receptor and well-understood. The Phase 3 trial in GH-deficient elderly patients was disappointing enough that the program was shelved, which is a real mark against it. The Phase 3 failure doesn’t invalidate the Phase 2 biology, but it does tell you the clinical hypothesis didn’t hold at the population level for the intended indication. The water retention and insulin resistance signal at sustained doses also complicates interpretation in any metabolic research context where you need a clean readout.

Honestly, MK-677 is more useful as a research tool than as a frontier compound. If you’re studying the GH axis, IGF-1-dependent anabolism, or ghrelin signaling and body composition, MK-677 gives you sustained once-daily GHS-R1a activation that no peptide GHRP can match practically. There’s also ongoing interest in sleep architecture effects, since GHS-R1a expression in hypothalamic circuits appears to influence slow-wave sleep independent of GH secretion. That secondary biology is arguably the fresher angle right now, though the evidence is early.

But lets be honest about the ceiling. A compound developed in the early 1990s with a well-characterized single receptor target and a failed Phase 3 is not where the frontier is. It scores in the lower established-active range: genuinely useful, real clinical data, best-in-class on oral delivery, but not a primary target for investigators chasing the next major finding in this space.

Novelty

32

Mechanism promise

42

In-category differentiation

60

Evidence quality

52

Translational signal

48

Research bench value

62

Rationale MK-677 is the only orally bioavailable non-peptide ghrelin receptor agonist with genuine Phase 2 clinical data, giving it real bench value for GH/IGF-1 axis research. A failed Phase 3, well-characterized single-receptor mechanism, and three decades of age keep novelty and translational scores firmly in the established range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Orally active non-peptide ghrelin receptor agonist

A Merck-developed orally bioavailable non-peptide ghrelin receptor agonist that produces sustained GH and IGF-1 elevation with once-daily oral dosing.

Abstract

MK-677 (Ibutamoren; CAS 159752-10-0; molecular formula C27H36N4O5S; molecular weight 528.66) is a non-peptide ghrelin receptor agonist developed by Merck in the 1990s. Unlike the peptide GHRPs, MK-677 is orally bioavailable and produces sustained GH and IGF-1 elevation over 24 hours with once-daily dosing. Phase 2 trials in elderly subjects showed sustained increases in GH, IGF-1, and lean body mass over 12 to 24 month treatment periods. The compound did not advance to FDA approval; the program was deprioritized after disappointing Phase 3 results in the GHD elderly population. The compound is sold as a research chemical/dietary supplement in some markets, though FDA has issued warnings against its sale as a supplement. Pharmacokinetics: plasma half-life 4 to 6 hours; high oral bioavailability; hepatic CYP3A4 metabolism. Doses are typically 10 to 25 mg orally once daily, usually at bedtime to align with the natural GH pulse. Adverse events include increased appetite, water retention, and modest insulin resistance with chronic high-dose use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-078Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 51 52 53 54 55 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.